Stiolto Respimat is tiotropium and olodaterol.
- TRADE NAMES: Spiriva (Boehringer Ingelheim); Stiolto Respimat (Boehringer Ingelheim)
- INDICATIONS: Bronchospasm (associated with COPD)
- CLASS: Anticholinergic, Muscarinic antagonist
- HALF-LIFE: 5–6 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetylcholinesterase inhibitors, Anticholinergics, Antihistamines, Botulinum Toxin (A & B), Cannabinoids, Conivaptan, Disopyramide, Domperidone, Haloperidol, Ketoconazole, Levodopa, MAO inhibitors, Memantine, Metoclopramide, Nefopam, Parasympathomimetics, PEG-Interferon, Phenothiazines, Potassium chloride, Pramlintide, Secretin, Sublingual nitrates, Tricyclic antidepressants
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tiotropium in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
